To include your compound in the COVID-19 Resource Center, submit it here.

Orencia abatacept: Phase IIIb data

The double-blind, international Phase IIIb AVERT trial in 351 patients with early RA showed that first-line treatment with once-weekly 125 mg subcutaneous Orencia plus methotrexate for 12 months met the co-primary endpoints of a greater

Read the full 351 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers